This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Integer (ITGR) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 5.15% and 2.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences (SGHT) delivered earnings and revenue surprises of 19.35% and 0.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 4.84% and 0.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 37.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences (SGHT) to Expand in Europe With New Launch
by Zacks Equity Research
By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 22.58% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.29% and 5.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of -34.85% and 2.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 44.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Inc. (STXS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 23.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.
Will Modest Top-Line Growth Aid Akamai (AKAM) Q3 Earnings?
by Zacks Equity Research
Akamai (AKAM) is expected to have recorded year-over-year higher third-quarter 2022 revenues driven by growth in its security business.
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -8.51% and 17.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.